PENSACOLA, FL, April 9, 2025 - ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research, announced a new strategic partnership with Xincere, a leading provider of Decentralized Clinical Trial (DCT) platform solutions in China and Asia.
Xincere's platform includes a comprehensive suite of solutions, including eCOA, Scale Management, Rater Training, eDiary, eConsent, TeleVisit, and more. With its locally compatible integrated eCOA solution, Xincere boasts numerous successful Phase II/III clinical trial projects and has pioneered the application of remote visit solutions in China.
ActiGraph’s AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. This strategic partnership enables Chinese pharmaceutical and biotech researchers to better collect real-world data using our portfolio of device and software solutions. This type of data enables more comprehensive and patient-centric measures that can reveal unique clinical insights to inform drug development programs.
"Chinese sponsors have unique operational, scientific, and regulatory challenges when utilizing DHT measures" said Christine Guo, Chief Scientific Officer at ActiGraph. “We’re excited to begin collaborating with Xincere to offer a comprehensive suite of digital measures.”
“Xincere and ActiGraph have forged a strategic partnership aimed at revolutionizing clinical trial endpoint innovation through advanced AI and data-driven solution,” said Kevin Lin, Chief Executive Officer at Xincere. “We’re eager to bring the best combined, AI-driven DCT and DHT solution to China and Asia, for the benefit of patients and sponsors here.”
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We empower biopharma companies to unleash the potential of big data and AI with a device-inclusive digital trial platform backed by proven operational, scientific, and regulatory expertise. Used in nearly 250 industry-sponsored clinical trials and appearing in over 25K published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.
About Xincere
Shanghai Xincere Med Tech Inc. is the premier provider of Decentralized Clinical Trial (DCT) platform solutions in China, specializing in the development of a patient-centric intelligent platform tailored for remote clinical trials. Leveraging the application of digital technology in clinical trials, Xincere is committed to enhancing the accessibility of clinical trials, mitigating the burden on patients, elevating the quality and efficiency of clinical studies, and minimizing the cost of drug research and development.